Download
s00345-021-03873-5.pdf 822,71KB
WeightNameValue
1000 Titel
  • Therapy of clinical stage IIA and IIB seminoma: a systematic review
1000 Autor/in
  1. Heinzelbecker, Julia |
  2. Schmidt, Stefanie |
  3. Lackner, Julia |
  4. Busch, Jonas |
  5. Bokemeyer, Carsten |
  6. Classen, Johannes |
  7. Dieing, Annette |
  8. Hakenberg, Oliver |
  9. Krege, Susanne |
  10. Papachristofilou, Alexandros |
  11. Pfister, David |
  12. Ruf, Christian |
  13. Schmelz, Hans |
  14. Schmidberger, Heinz |
  15. Souchon, Rainer |
  16. Winter, Christian |
  17. Zengerling, Friedemann |
  18. Kliesch, Sabine |
  19. Albers, Peter |
  20. Oing, Christoph |
1000 Erscheinungsjahr 2021
1000 Publikationstyp
  1. Artikel |
1000 Online veröffentlicht
  • 2021-11-15
1000 Erschienen in
1000 Quellenangabe
  • 40(12):2829-2841
1000 Copyrightjahr
  • 2021
1000 Lizenz
1000 Verlagsversion
  • https://doi.org/10.1007/s00345-021-03873-5 |
  • https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9712301/ |
1000 Publikationsstatus
1000 Sprache der Publikation
1000 Abstract/Summary
  • Purpose!#!The optimal treatment for clinical stage (CS) IIA/IIB seminomas is still controversial. We evaluated current treatment options.!##!Methods!#!A systematic review was performed. Only randomized clinical trials and comparative studies published from January 2010 until February 2021 were included. Search items included: seminoma, CS IIA, CS IIB and therapy. Outcome parameters were relapse rate (RR), relapse-free (RFS), overall and cancer-specific survival (OS, CSS). Additionally, acute and long-term side effects including secondary malignancies (SMs) were analyzed.!##!Results!#!Seven comparative studies (one prospective and six retrospective) were identified with a total of 5049 patients (CS IIA: 2840, CS IIB: 2209). The applied treatment modalities were radiotherapy (RT) (n = 3049; CS IIA: 1888, CSIIB: 1006, unknown: 155) and chemotherapy (CT) or no RT (n = 2000; CS IIA: 797, CS IIB: 1074, unknown: 129). In CS IIA, RRs ranged from 0% to 4.8% for RT and 0% for CT. Concerning CS IIB RRs of 9.5%-21.1% for RT and of 0%-14.2% for CT have been reported. 5-year OS ranged from 90 to 100%. Only two studies reported on treatment-related toxicities.!##!Conclusions!#!RT and CT are the most commonly applied treatments in CS IIA/B seminoma. In CS IIA seminomas, RRs after RT and CT are similar. However, in CS IIB, CT seems to be more effective. Survival rates of CS IIA/B seminomas are excellent. Consequently, long-term toxicities and SMs are important survivorship issues. Alternative treatment approaches, e.g., retroperitoneal lymph node dissection (RPLND) or dose-reduced sequential CT/RT are currently under prospective investigation.
1000 Sacherschließung
lokal Topic Paper
lokal Seminoma
lokal Humans [MeSH]
lokal Prospective Studies [MeSH]
lokal Systematic review
lokal Testicular Neoplasms/radiotherapy [MeSH]
lokal Retrospective Studies [MeSH]
lokal Neoplasm Recurrence, Local/pathology [MeSH]
lokal Neoplasms, Second Primary/pathology [MeSH]
lokal Neoplasm Staging [MeSH]
lokal Male [MeSH]
lokal Seminoma/drug therapy [MeSH]
lokal Seminoma/radiotherapy [MeSH]
lokal Toxicity
lokal Testicular Neoplasms/drug therapy [MeSH]
lokal CS IIA/B
lokal Treatment
lokal Testicular cancer
1000 Liste der Beteiligten
  1. https://orcid.org/0000-0001-8993-7171|https://frl.publisso.de/adhoc/uri/U2NobWlkdCwgU3RlZmFuaWU=|https://frl.publisso.de/adhoc/uri/TGFja25lciwgSnVsaWE=|https://frl.publisso.de/adhoc/uri/QnVzY2gsIEpvbmFz|https://frl.publisso.de/adhoc/uri/Qm9rZW1leWVyLCBDYXJzdGVu|https://frl.publisso.de/adhoc/uri/Q2xhc3NlbiwgSm9oYW5uZXM=|https://frl.publisso.de/adhoc/uri/RGllaW5nLCBBbm5ldHRl|https://frl.publisso.de/adhoc/uri/SGFrZW5iZXJnLCBPbGl2ZXI=|https://frl.publisso.de/adhoc/uri/S3JlZ2UsIFN1c2FubmU=|https://frl.publisso.de/adhoc/uri/UGFwYWNocmlzdG9maWxvdSwgQWxleGFuZHJvcw==|https://frl.publisso.de/adhoc/uri/UGZpc3RlciwgRGF2aWQ=|https://frl.publisso.de/adhoc/uri/UnVmLCBDaHJpc3RpYW4=|https://frl.publisso.de/adhoc/uri/U2NobWVseiwgSGFucw==|https://frl.publisso.de/adhoc/uri/U2NobWlkYmVyZ2VyLCBIZWlueg==|https://frl.publisso.de/adhoc/uri/U291Y2hvbiwgUmFpbmVy|https://frl.publisso.de/adhoc/uri/V2ludGVyLCBDaHJpc3RpYW4=|https://frl.publisso.de/adhoc/uri/WmVuZ2VybGluZywgRnJpZWRlbWFubg==|https://frl.publisso.de/adhoc/uri/S2xpZXNjaCwgU2FiaW5l|https://frl.publisso.de/adhoc/uri/QWxiZXJzLCBQZXRlcg==|https://orcid.org/0000-0001-5578-3418
1000 Hinweis
  • DeepGreen-ID: 15bf708c51234793aeeb44370473d77c ; metadata provieded by: DeepGreen (https://www.oa-deepgreen.de/api/v1/), LIVIVO search scope life sciences (http://z3950.zbmed.de:6210/livivo), Crossref Unified Resource API (https://api.crossref.org/swagger-ui/index.html), to.science.api (https://frl.publisso.de/), ZDB JSON-API (beta) (https://zeitschriftendatenbank.de/api/), lobid - Dateninfrastruktur für Bibliotheken (https://lobid.org/resources/search)
1000 Label
1000 Dateien
  1. Therapy of clinical stage IIA and IIB seminoma: a systematic review
1000 Objektart article
1000 Beschrieben durch
1000 @id frl:6447693.rdf
1000 Erstellt am 2023-05-03T16:08:37.698+0200
1000 Erstellt von 322
1000 beschreibt frl:6447693
1000 Zuletzt bearbeitet Fri Oct 20 21:02:47 CEST 2023
1000 Objekt bearb. Fri Oct 20 21:02:47 CEST 2023
1000 Vgl. frl:6447693
1000 Oai Id
  1. oai:frl.publisso.de:frl:6447693 |
1000 Sichtbarkeit Metadaten public
1000 Sichtbarkeit Daten public
1000 Gegenstand von

View source